Stockreport

Acoramidis Significantly Reduces All-cause Mortality in the Overall ATTR-CM Variant and V142I (V122I) Populations

BridgeBio Pharma, Inc.  (BBIO) 
Last bridgebio pharma, inc. earnings: 3/2 08:29 am Check Earnings Report
PDF - Simultaneously published in JAMA Cardiology along with moderated posters at AHA, acoramidis demonstrated: 59% risk reduction in ACM in the ATTR-CM variant population [Read more]